ANRO Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (ANRO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.71 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Alto Neuroscience, Inc.
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.
Sector
Healthcare
Industry
Biotechnology